Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical TrialRan Reshef, David Porter, Noelle V. Frey et al.|Transplantation and Cellular Therapy|2018Cited by 31
Extended Course of Maraviroc, a CCR5 Antagonist, Is Safe and Effective in Graft-Versus-Host Disease Prophylaxis. Final Results of a Phase II StudyRan Reshef, David L. Porter, James K. Mangan et al.|Transplantation and Cellular Therapy|2017Cited by 1
D67. Functional Outcomes following Microsurgical Thoracic Duct Lymphovenous BypassJ. Reed McGraw, Stephen J. Kovach, Yoshiko Toyoda et al.|Plastic & Reconstructive Surgery Global Open|2023Cited by 0